心不全および慢性腎臓病患者におけるAZD9977とダパグリフロジンの有効性、安全性および忍容性

基本情報

NCT ID

NCT04595370

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

153

治験依頼者名

AstraZeneca

概要

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF \[below 60%\]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR \[between ≥ 20 and ≤ 60 mL/min/1.73 m\^2, with at least 20% of participants with eGFR ≥ 20 to \<30 mL/min/1.73\^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m\^2\]).

対象疾患

介入

依頼者（Sponsor）